dupilumab
regeneron,sanofi
['dupixent', 'derm', 'prurigo nodularis', '$sny', 'sanofi', 'regeneron', '$regn']
regeneron and sanofi presented positive results from the second of two phase 3 trials evaluating dupixent in adults with uncontrolled prurigo nodularis in a late-breaking session at the eadv 2022 congress! $regn $sny #pharma #dermatology #eadvcongress 
Investor Relations & PR firm working w/ growth #LifeSciences #Tech #Mining #Consumer companies to connect #WallStreet #Investors — No investment advice / DYODD